325 related articles for article (PubMed ID: 36839156)
1. Anticancer Mechanism of Flavonoids on High-Grade Adult-Type Diffuse Gliomas.
Wong SC; Kamarudin MNA; Naidu R
Nutrients; 2023 Feb; 15(4):. PubMed ID: 36839156
[TBL] [Abstract][Full Text] [Related]
2. The flavonoid rutin and its aglycone quercetin modulate the microglia inflammatory profile improving antiglioma activity.
da Silva AB; Cerqueira Coelho PL; das Neves Oliveira M; Oliveira JL; Oliveira Amparo JA; da Silva KC; Soares JRP; Pitanga BPS; Dos Santos Souza C; de Faria Lopes GP; da Silva VDA; de Fátima Dias Costa M; Junier MP; Chneiweiss H; Moura-Neto V; Costa SL
Brain Behav Immun; 2020 Mar; 85():170-185. PubMed ID: 31059805
[TBL] [Abstract][Full Text] [Related]
3. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
4. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas.
Takano S; Ishikawa E; Sakamoto N; Matsuda M; Akutsu H; Noguchi M; Kato Y; Yamamoto T; Matsumura A
Brain Tumor Pathol; 2016 Apr; 33(2):107-16. PubMed ID: 26968173
[TBL] [Abstract][Full Text] [Related]
6. Revealing the Mechanism of EGCG, Genistein, Rutin, Quercetin, and Silibinin Against hIAPP Aggregation via Computational Simulations.
Wang Y; Lv Y; Jin L; Liang G
Interdiscip Sci; 2020 Mar; 12(1):59-68. PubMed ID: 31894470
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
[TBL] [Abstract][Full Text] [Related]
8. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
Lefranc F; Rynkowski M; DeWitte O; Kiss R
Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
[TBL] [Abstract][Full Text] [Related]
9. The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021.
Perez A; Huse JT
Curr Neurol Neurosci Rep; 2021 Nov; 21(12):67. PubMed ID: 34817712
[TBL] [Abstract][Full Text] [Related]
10. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist.
Broniscer A; Gajjar A
Oncologist; 2004; 9(2):197-206. PubMed ID: 15047924
[TBL] [Abstract][Full Text] [Related]
11. P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas.
Zou H; Wen C; Peng Z; Shao YΥ; Hu L; Li S; Li C; Zhou HH
Oncol Rep; 2018 Feb; 39(2):501-510. PubMed ID: 29207176
[TBL] [Abstract][Full Text] [Related]
12. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
13. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
[TBL] [Abstract][Full Text] [Related]
14. Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas.
Kazarian E; Marks A; Cui J; Darbinyan A; Tong E; Mueller S; Cha S; Aboian MS
Sci Rep; 2021 Jul; 11(1):14377. PubMed ID: 34257334
[TBL] [Abstract][Full Text] [Related]
15. Paediatric-type diffuse low-grade gliomas: a clinically and biologically distinct group of tumours with a favourable outcome.
Fabbri VP; Caporalini C; Asioli S; Buccoliero A
Pathologica; 2022 Dec; 114(6):410-421. PubMed ID: 36534420
[TBL] [Abstract][Full Text] [Related]
16. Flavonoids Synergistically Enhance the Anti-Glioblastoma Effects of Chemotherapeutic Drugs.
Zhai K; Mazurakova A; Koklesova L; Kubatka P; Büsselberg D
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944485
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment.
Ryall S; Tabori U; Hawkins C
Brain Tumor Pathol; 2017 Apr; 34(2):51-61. PubMed ID: 28342104
[TBL] [Abstract][Full Text] [Related]
18. The Pathological Evaluation of Autophagy-Related Protein (LC3B) and Its Association with the Infiltration of Immune Cells in Glioma.
Mohammed SM; Elesawy YF; Abd El Aziz AM; Khairy RA
Asian Pac J Cancer Prev; 2022 May; 23(5):1777-1784. PubMed ID: 35633564
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of dietary flavonoids on drug metabolizing and antioxidant enzymes in female rat.
Breinholt V; Lauridsen ST; Dragsted LO
Xenobiotica; 1999 Dec; 29(12):1227-40. PubMed ID: 10647909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
